# AZD5305 hADME in Patients With Advanced Solid Malignancies

Source: https://onco.cc/trials/nct06713369/  
OnCo record `nct06713369` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT06713369 as recruiting, last updated 2026-06-24. Enrolment is 8 planned participants, an estimate. Interventions: Saruparib (AZD5305), [14C]-AZD5305 microtracer, [14C]-AZD5305 (therapeutic dose). Primary measures include Absolute bioavailability (F) of Saruparib; Total radioactivity recovery in urine and faeces. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT06713369
- Phase: 1
- Setting: A Phase I, Open-label Study to Assess the Absolute Bioavailability of Saruparib (AZD5305) and Absorption, Distribution, Metabolism, and Excretion (ADME) of [14C]-Saruparib ([14C]-AZD5305) in Patients With Advanced Solid Malignancies
- Sponsor: AstraZeneca

## Sources

- ClinicalTrials.gov NCT06713369: https://clinicaltrials.gov/study/NCT06713369

## Connected records

- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Saruparib](https://onco.cc/drugs/saruparib/)

---
JSON: https://onco.cc/api/v1/entities/nct06713369.json